What Cannabis Rescheduling Means for your Business
In a landmark announcement on December 18, 2025, the federal government officially rescheduled cannabis from the most restrictive Schedule I category to the less restrictive Schedule III under the Controlled Substances Act (CSA).
The federal government’s decision to reschedule cannabis reflects a long-overdue alignment with modern science. Extensive peer-reviewed research, real-world clinical use, and patient outcomes have established that cannabis has accepted medical applications and a safety profile inconsistent with the most restrictive Schedule I classification. Following a comprehensive scientific and medical review, the U.S. Department of Health and Human Services concluded that cannabis meets the criteria for Schedule III, recognizing both its therapeutic value and a lower potential for abuse than substances in Schedules I and II. This change brings federal policy closer to scientific consensus, removes unnecessary barriers to legitimate medical research, and signals a shift toward evidence-based decision-making.
At Dutchie, we’ve worked tirelessly alongside our customers and partners toward this outcome for years, putting thousands of hours and millions of dollars towards cannabis policy reform as co-chairs of the Coalition for Cannabis Scheduling Reform. Under Dutchie’s leadership, the CCSR convened cannabis enterprises and experts across the scientific and legal communities, and engaged with federal policymakers across two administrations to share research, analysis, and industry perspective. Dutchie also helped rally support from state attorneys general and worked through key considerations, including potential conflicts with U.S. obligations under international treaties.
Impact 1. Tax Relief: Ending the Burden of 280E
With the reclassification of cannabis to Schedule III, state legal cannabis businesses will no longer be subject to the punitive restrictions of Internal Revenue Code Section 280E. This change represents one of the most consequential economic shifts in the history of the regulated cannabis industry.
For years, Section 280E forced cannabis operators to pay taxes on gross income rather than net income, disallowing ordinary and necessary business deductions such as payroll, rent, utilities, marketing, and professional services. The result was artificially inflated effective tax rates that constrained reinvestment, distorted margins, and placed cannabis businesses at a structural disadvantage compared to other regulated industries.
The removal of 280E allows cannabis businesses to deduct ordinary operating expenses like other lawful enterprises, freeing up capital that can be reinvested into growth, compliance, employee compensation, and long-term operational stability. By eliminating one of the most punitive barriers to growth, this shift opens the door for more operators, talent, and partners to confidently enter and scale within the industry.
While operators will continue to navigate complex state and federal regulatory requirements, rescheduling meaningfully reduces one of the most anomalous aspects of federal cannabis policy and signals a move toward normalization. For many operators, the end of 280E represents the most impactful near-term financial relief the industry has ever experienced - unlocking resources that support healthier businesses, stronger workforces, increased institutional participation, and a more sustainable, mature market.
Impact 2. Banking & Payments: Reduced Friction, Increased Stability
Rescheduling cannabis to Schedule III reduces one of the core federal barriers that has long complicated access to banking and payment services. By removing cannabis from Schedule I, the most restrictive category under the Controlled Substances Act, rescheduling meaningfully improves how financial institutions assess legal and compliance risk when working with cannabis businesses.
While rescheduling alone does not eliminate all banking challenges, it is expected to increase institutional willingness to serve the industry over time: supporting more stable banking relationships, improved payment reliability, and fewer cash-based workarounds. This progress strengthens day-to-day operations, enhances compliance, and lays the groundwork for broader financial normalization.
Impact 3. Legitimacy & Market Confidence
Moving cannabis to Schedule III represents a fundamental shift in how the federal government, and society at large, views the plant. Recognizing accepted medical use carries meaningful signaling power across the broader economy and marks a turning point in how the cannabis industry operates.
In practice, increased federal legitimacy can improve relationships with landlords, insurers, employers, investors, and strategic partners, reducing stigma and uncertainty that have historically constrained growth. For operators, this translates into a more predictable business environment and greater confidence to invest for the long term.
Impact 4. Research & Medical Advancement
Rescheduling cannabis removes significant barriers that have limited scientific and medical research for decades. Schedule III status simplifies research approvals and expands opportunities for clinical study, enabling better data on efficacy, safety, dosing, and outcomes.
Over time, increased research access can drive higher product standards, inform smarter regulation, and lay the groundwork for a federally recognized legalization framework - benefiting patients, providers, and the industry as a whole.
Conclusion
The rescheduling of cannabis to Schedule III marks a meaningful step toward a more rational, science-based federal framework. By easing the burden of punitive tax treatment, reducing friction in banking and payments, increasing market legitimacy, and unlocking research opportunities, rescheduling delivers real, practical benefits for operators and the broader ecosystem.
Throughout the federal review and decision-making process, Dutchie represented the perspectives of its customers in Washington and engaged with policymakers, regulators, and industry partners to support evidence-based reform. While rescheduling does not resolve every regulatory challenge facing the industry, it establishes a stronger, more stable foundation for compliance, investment, and long-term growth. Dutchie remains committed to advocating for policies that support a healthy, inclusive cannabis ecosystem and help businesses operate, scale, and succeed alongside the broader economy.
